The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.
Looking for leads, investment insights, or competitive intelligence?
News about Biogen
Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.
It will cost more than $700,000 per year.
Companies are increasingly joining forces to tackle chronic diseases using high-tech devices.